Endothelial functional activity and circadian blood pressure dynamics in hypertensive patients treated with angiotensin receptor antagonists
https://doi.org/10.15829/1728-8800-2011-5-20-25
Abstract
Aim. To assess the associations between endothelial functional activity and circadian blood pressure profile (CBPP) in hypertensive patients (Stage I-II arterial hypertension, uncontrolled in ambulatory settings) who were administered candesartan and losartan.
Material and methods. The study included 60 patients, aged 35-65 years. All participants were divided into two groups: Group I (n=31; 15 men, 16 women; mean age 46,1±7,1 years) receiving losartan, and Group II (n=29; 12 men, 17 women; mean age 47,2±6,8 years) receiving candesartan. The examination included 24-hour BP monitoring (BPM) and the measurement of serum levels of nitric oxide (NO) stable end products, as the markers of endothelial functional activity.
Results. Candesartan demonstrated a more pronounced beneficial effect on several 24-hour BPM parameters, compared to losartan. The candesartan group showed a significant increase in serum NO (NOx) levels (from 38,56±4,68 to 89,17±10,5 μmol/l; p<0,0001). In the losartan group, serum NO (NOx) levels increased from 37,19±2,43 to 59,32±7,03 μmol/l (p<0,001). Serum NO levels significantly correlated with the main CBPP parameters for diastolic BP, both at baseline and during the candesartan treatment. Similarly, the losartan group demonstrated a significant negative correlation between NO levels and 24-hour BPM parameters.
Conclusion. The beneficial effects on CBPP and endothelial functional activity were more pronounced for candesartan, compared to losartan.
About the Authors
N. G. Poteshkina
Russian State Medical University
Russian Federation
Moscow
Russian Federation
Moscow
G. B. Selivanova
Russian State Medical University
Russian Federation
Moscow
Russian Federation
Moscow
T. Zh. Zhalsaraev
Russian State Medical University
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Чазова И.Е., Ратова Л.Г. Первое поколение сартанов: есть ли перспективы? Системные гипертензии 2010; 4. Кардиология. Cons med. Электронный ресурс [http://www.conmed.ru/magazines/magazines/special/gypertens/article/20372].
2. Бова А.А. Место антагонистов рецепторов ангиотензина II в клинической практике. Медицинские новости 2009; 6: 11-5.
3. Карпов Ю.А. Лечение больных сердечно-сосудистыми заболеваниями: роль блокады РААС с помощью сартанов. РМЖ 2008; 16 (11): 1554-7.
4. Carey RM, Zhi-Qin Wang, Siragy HM. Role of the Angiotensin Type 2 Receptor in the Regulation of Blood Pressure and RenalFunction. Hypertension 2000; 35(5): 15.
5. Siragy HM, de Gasparo M, Carey RM. Angiotensin type 2 receptor mediates valsartan-induced hypotension in conscious rats. Hypertension 2000; 35(5): 1074-7.
6. Stoll M, Steckelings M, Paul M, et al. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995; 95: 651-7.
7. Taddei S, Virdis A, Chiadoni L, Salvetti A. The pivotal role of endotelium in hypertension. Medicographia. Issue 59. 1999; 21 (1): 22-9.
8. Метельская В.А., Гуманова Н.Г. Скрининг-метод определения уровня метаболитов оксида азота в сыворотке крови человека. Клин лаб диагн 2005; 6:15-8.
9. Welch WJ, Wilcox CS. Receptor antagonist combats oxidative stress and restores nitric oxide signaling in the SHR. Kidney Int 2001; 59(4):1257-63.
10. Booz GW, Baker KM. Role of type 1 and type 2 angiotensin receptors in angiotensin II-induced cardiomyocyte hypertrophy. Hypertension 1996; 28: 635-40.
11. Chung O, Unger T. Angiotensin II receptor blockade and end organ protection. Am J Hypertension 1999; 12: 150-6.
12. Schiffrin EL, Park JB, Touyz RM. Correction of Arterial Structure and Endothelial Dysfunction in Human Essential Hypertension by the Angiotensin Receptor Antagonist Losartan. Circulation 2000; 101: 1653.
13. Gohlke P, Pees C, Unger T. AT2-receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanisms. Hypertension 1998; 3: 349-55.
14. Habib JB, Bossaller C, Wells S, et al. Preservation of endotheliumdepent vascular relaxation in cholesterol-fed rabbit by treatment with the calcium blocker PN 200110. Circ Res 1986; 58: 305-9.
15. Hsueh WA, Anderson PW. Hypertension, the endothelial cell, and the vascular complications of diabetes mellitus [clinical conference]. Hypertension 1992; 20(2): 253-63.
16. Ledingham JM, Laverty R. Basilar artery remodelling in the genetically hypertensive rat: effects of nitric oxide synthase inhibition and treatment with valsartan and enalapril. Clin Exp Pharmacol Physiol 2000; 27(8): 642-6.
17. Nakajima M, Hutchinson H, Morishita R, et al. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects ofthe AT1 receptor: Gain of functionstudy using in vivo gene transfer. Proc Natl Acad Sci USA 1995; 92: 10663-7.
18. Qadri F, Arens T, Schwartz EC, et al. Angiotensin-converting enzyme inhibitors and AT1-receptor antagonist restore nitric oxide synthase (NOS) activity and neuronal NOS expression in the adrenal glands of spontaneously hypertensive rats. Jpn J Pharmacol 2001; 85(4): 365-9.
19. Небиеридзе Д.В. Дисфункции эндотелия и ее коррекции при артериальной гипертонии. РМЖ 2006; 14(2): 127-32.
20. Ringborg A, Martinell M, Stalhammar J, et al. Resource use and costs of type 2 diabetes in Swede — estimates from population-based register data. Int J Clin Pract 2008; 62 (5): 708-16.
21. Young JB, Dunlap ME, Pfeffer MA, et al. Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM lowleft ventricular ejection fraction trials. Circulation 2004; 110(17): 2618-26.
22. Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348 (7): 583-92.
23. Задионченко В.С., Адашева Т.В., Сандомирская А.П. Дисфункция эндотелия и артериальная гипертония: терапевтические возможности. МГМСУ им. Н.А. Семашко. Электронный ресурс: [http://med-lib.ru/speclit/card/55.php] 2010.
24. Cardio.medi.ru. Место сартанов в лечении артериальной гипертонии. Электронный ресурс: [<a href=http://medi.ru/doc/a1511503.htm>] 3, 2009.
25. Вёрткин А.Л., Скотников А.С. Артериальная гипертензия: перспективы современной фармакотерапии и значение высокоселективных блокаторов ангиотензиновых рецепторов. РМЖ 2009; 17(18): 1188-93.
26. Кобалава Ж.Д., Шаварова Е.К. Антагонисты рецепторов ангиотензина II в кардиологической практике: современный взгляд на проблему. РМЖ 2008; 16(11): 1609-15.
27. Национальные клинические рекомендации. Сборник под ред. Р.Г. Оганова. 2-е издание. М.: Изд-во “Силицея-Полиграф” 2009; 528 c.
28. Linder L, Kiowski W, Buhler FR, Luscher TF. Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo: blunted response in essential hypertension. Circulation 1990; 81: 1762-7.
29. Rizzoni D, Porteri E, Castellano M, et al. Endothelial dysfunction in hypertension is independent from the etiology and from vascular structure. Hypertension 1998; 31(pt 2): 335-41.
30. Vanhoutte PM. Endothelial dysfunction in hypertension. J Hypertens Suppl 1996; 14(5): S83-93.
31. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endotheliumdependent vascular relaxation of patients with essential hypertension Circulation 1993; 87: 1468-74.
Review
For citations:
Poteshkina N.G., Selivanova G.B., Zhalsaraev T.Zh. Endothelial functional activity and circadian blood pressure dynamics in hypertensive patients treated with angiotensin receptor antagonists. Cardiovascular Therapy and Prevention. 2011;10(5):20-25. (In Russ.) https://doi.org/10.15829/1728-8800-2011-5-20-25
Views:
448
Email this article 
